510(k) Summary
superDimension, Ltd.
Special 510(k)
superDimension® i·Logic™ inReach® System
Addition of Edge™ Catheter System

OCT - 7 2010

K102604

Date Prepared:

09/07/2010

510(k) Applicant:

superDimension, Ltd.
8 Hamenofim St., P.O. Box 2045
Herzliya 46120
Israel
Ph: +972-(0)9-971-3700
Fax: +972-(0)9-971-3701

510(k) Application Correspondent:

Jonathan Kovach
Vice President, Quality and Regulatory Affairs
superDimension, Inc.
161 Cheshire Lane, Suite 100
Minneapolis, MN 55441
Phone: 763-210-4015
Cell : 763-360-4984
Fax : 763-210-4098
Email : jkovach@superdimension.com

Name of Device :

Trade Name :	superDimension i·Logic inReach System superDimension inReach System superDimension/Bronchus
Common Name:	Bronchoscope
Classification Name:	Computed tomography x-ray system 21 CFR Part 892.1750 Product code JAK

Equivalent Legally-Marketed Device:

superDimension i·Logic inReach System, K071473/K092365

Description:

The superDimension i·Logic inReach System is a device that guides a bronchoscope and endoscopic tools to a target in or adjacent to the bronchial tree on a path identified by CT scan. The superDimension i·Logic inReach System also allows visualization of the target and the interior of the bronchial tree; placement of catheters in the bronchial tree; and placement of radiosurgical and dye markers into soft lung tissue to guide radiosurgery and thoracic surgery.

superDimension is introducing the Edge Catheter System for use with the superDimension i·Logic inReach System. The i·Logic inReach System accomodates both the Edge Catheter and the currently available inReach Catheter System.

Intended Use:

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

Summary of Characteristics Compared to Predicate Device:

The Edge Catheter System is an alternate catheter system for use with the superDimension i·Logic inReach System. The Edge Catheter System includes modifications to the existing inReach Catheter System, procedure software, and instructions for use. The Edge Catheter and inReach Catheter systems may both be used with the superDimension i·Logic inReach System. No changes are being made to the electromagnetic components or fundamental scientific technology of the i·Logic inReach System.

Performance Data:

The Edge Catheter System, i·Logic inReach Software, and Instructions for Use were subjected to the superDimension design control process. Risk Management was performed to analyze the potential hazards associated with the changes. Appropriate design verification and validations were performed to assure the superDimension i·Logic inReach System continues to be safe and effective for its intended use.

Clinical Data:

Clinical tests were not required to validate the changes to the superDimension inReach System.

Conclusion:

The superDimension i·Logic inReach System with the Edge Catheter is safe and effective for its intended use.

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room – WO66-G609
Silver Spring, MD 20993-0002

SuperDimension, Ltd.
% Mr. Jonathan Kovach
Vice President, Quality and Regulatory Affairs
161 Cheshire Lane, Suite 100
MINNEAPOLIS MN 55441

OCT - 7 2010

Re: K102604
Trade/Device Name: superDimension® i-Logic™ inReach® System with Edge™ Catheter
Regulation Number: 21 CFR 892.1750
Regulation Name: Computed tomography x-ray system
Regulatory Class: II
Product Code: JAK
Dated: September 7, 2010
Received: September 10, 2010

Dear Mr. Kovack:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

David G. Brown, Ph.D.
Acting Director
Division of Radiological Devices
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use

OCT - 7 2010

510(k) Number (if known): K102604

Device Name: superDimension® i·Logic™ inReach® System with Edge™ Catheter

Indications for Use:

Indicated for displaying images of the tracheobronchial tree to aid the physician in guiding endoscopic tools or catheters in the pulmonary tract and to enable marker placement within soft lung tissue. It does not make a diagnosis and is not an endoscopic tool. Not for pediatric use.

Prescription Use ✓ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

(Division Sign-Off)
Division of Radiological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety

510K K102604